BMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE